# Prime Medicine Inc. (PRME) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.70, market value $671 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Prime Medicine Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 144.9×**. Each dollar of revenue is priced at 144.9×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 16.4×**. The shares trade at 16.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -23.4%** (5-yr avg -28.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -166.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -58.7%**. Each dollar of assets produces -58.7% of profit.

## Growth
- **Revenue growth (1 yr): 55.3%** (5-yr -2.3%/yr). Revenue grew 55.3% over the last year, against -2.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 18.2%**. Earnings per share rose 18.2%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 4.84** (quick 4.84). Current assets cover the next year's liabilities 4.84 times.
- **Altman Z-score: 0.82**. A Z-score of 0.82 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Prime Medicine Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Prime Medicine Inc.; the consensus is strong_buy, with an average price target of $7.11 (+92% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 8.8%** (YTD 6.6%, 3-mo 20.9%). The shares are up 8.8% over twelve months including dividends.
- **From 52-week high: -46.7%** (38.6% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 2.35** (volatility 89%). Beta of 2.35 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PRME · Page: https://foliofundamentals.com/stocks/prme

Not investment advice.